PUBLISHER: The Business Research Company | PRODUCT CODE: 1855801
PUBLISHER: The Business Research Company | PRODUCT CODE: 1855801
An atopic dermatitis cream is a topical formulation, often corticosteroid-, emollient-, or non-steroidal-based, designed to soothe inflammation, relieve itching, and restore the skin barrier in patients with chronic eczema. These creams help maintain hydration, reduce flare-ups, and improve comfort in daily skin care.
The primary product categories of atopic dermatitis creams include corticosteroid creams, calcineurin inhibitor creams, PDE4 inhibitor creams, moisturizing creams, and others. Corticosteroid creams are topical medications applied directly to the skin to reduce inflammation, redness, and itching by modulating immune responses in conditions such as eczema. These products are used across pediatric, adult, and geriatric age groups and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The atopic dermatitis cream market research report is one of a series of new reports from The Business Research Company that provides atopic dermatitis cream market statistics, including the atopic dermatitis cream industry global market size, regional shares, competitors with the atopic dermatitis cream market share, detailed atopic dermatitis cream market segments, market trends, and opportunities, and any further data you may need to thrive in the atopic dermatitis cream industry. This atopic dermatitis cream market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The atopic dermatitis cream market size has grown strongly in recent years. It will grow from $4.99 billion in 2024 to $5.42 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period was driven by increasing awareness of skin health, rising prevalence of atopic dermatitis, growing demand for topical therapies, expansion of dermatology research, wider availability through retail and online channels, and supportive healthcare reimbursement policies.
The atopic dermatitis cream market size is expected to see strong growth in the next few years. It will grow to $7.50 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period is expected to be supported by higher demand for personalized dermatology solutions, growing adoption of digital health platforms for monitoring skin conditions, wider availability of over-the-counter non-steroidal creams, and greater focus on pediatric-friendly formulations. Key trends anticipated in the forecast period include the adoption of steroid-free formulations, advancements in biologic-inspired topicals, use of nanotechnology-based delivery systems, personalized treatment approaches, incorporation of natural and botanical ingredients, integration of digital adherence tools, and increased use of teledermatology platforms.
The increasing prevalence of eczema is expected to drive the expansion of the atopic dermatitis cream market in the future. Eczema is a skin disorder characterized by itching, redness, dryness, and inflammation. The need for eczema care is growing as more individuals experience allergies and sensitive skin conditions, increasing demand for effective treatments and skincare products. Atopic dermatitis cream helps treat eczema by reducing inflammation, calming itching, restoring the skin's natural barrier, and preventing further irritation or infection, thereby supporting healing and long-term skin health in affected areas. For example, in December 2024, the Royal Australian College of General Practitioners, a research institute based in Australia, reported that approximately sixteen percent of Australians suffer from eczema, with about twenty-five percent of these cases classified as severe. Thus, the rising prevalence of eczema is driving growth in the atopic dermatitis cream market.
Key players in the atopic dermatitis cream market are focusing on developing innovative steroid-free treatments, increasing patient access through insurance and support programs, and ensuring long-term management of the condition with safer topical options. Steroid-free therapies offer alternatives to corticosteroids by treating inflammation and skin issues safely without the risks associated with steroids. For instance, in July 2024, Arcutis Biotherapeutics Inc., a biopharmaceutical company based in the United States, introduced ZORYVE (roflumilast) cream 0.15 percent in the U.S. for the treatment of mild to moderate atopic dermatitis in adults and children aged six years and older. This once-daily steroid-free cream is formulated to provide rapid relief from itching, enhance disease clearance, and support long-term control without the common side effects linked to traditional topical treatments. ZORYVE is available at pharmacies with immediate insurance coverage under select pharmacy benefit manager contracts.
In October 2024, Organon & Co., a pharmaceutical company based in the United States, acquired Dermavant Sciences Ltd. for an undisclosed sum. This acquisition strengthens Organon's dermatology portfolio by adding VTAMA, a first-in-class nonbiologic, non-steroidal topical therapy for plaque psoriasis, which also has potential approval for atopic dermatitis. Dermavant Sciences Ltd. is a pharmaceutical company based in the United States specializing in therapeutic solutions for dermatological conditions.
Major players in the atopic dermatitis cream market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Viatris Inc, Regeneron Pharmaceuticals, Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Organon & Co., Galderma S.A., Incyte Corporation, Leo Pharma A/S, Almirall S.A., Boehringer Ingelheim, Arcutis Biotherapeutics Inc., Medimetriks Pharmaceuticals Inc.
North America was the largest region in the atopic dermatitis cream market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in atopic dermatitis cream report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the atopic dermatitis cream market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The atopic dermatitis cream market consists of sales of barrier repair creams, antihistamine-infused creams, ceramide-enriched creams, herbal and plant-based creams, and probiotic-infused creams. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Atopic Dermatitis Cream Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on atopic dermatitis cream market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for atopic dermatitis cream ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The atopic dermatitis cream market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.